Molecular Partners AG (MOLN) company profile

Molecular Partners AG is a clinical-stage biotechnology company that designs and develops Designed Ankyrin Repeat Protein (DARPin) therapeutics. The company concentrates primarily on oncology treatments, engineering custom protein drug candidates with distinct mechanisms of action. Its pipeline includes targeted radiopharmaceuticals such as Radio-DARPins and next-generation immune cell engagers like Switch-DARPins. Key investigational programs encompass MP0712, MP0726, MP0317, and MP0533, which target specific antigens in solid tumors and hematologic malignancies. Rather than serving direct retail customers, the company targets cancer patient populations and advances its programs both independently and through strategic co-development agreements with biopharmaceutical partners.

The company operates with an international workforce of more than 130 individuals. Clinical and research activities take place across multiple international jurisdictions, including clinical trials conducted in the United States and France, alongside compassionate care access in South Africa. The company maintains registered offices in the United States through its subsidiary in Cambridge and Concord, Massachusetts. Molecular Partners AG is headquartered in Schlieren, Switzerland.

Summary of the business section of Molecular Partners's latest annual report, written by StockData.

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“In 2025 we recorded a total of CHF 2.7 million in restructuring expenses following the reorganization announced in June 2025 where a total of 34 employees were affected.”